{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=gemcitabine&page=4", "query": { "intervention": "gemcitabine", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 1628, "total_pages": 163, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=gemcitabine&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=gemcitabine&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T05:02:35.277Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00095966", "title": "Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Pancreas", "Recurrent Pancreatic Cancer", "Stage II Pancreatic Cancer", "Stage III Pancreatic Cancer", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2004-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-02", "last_synced_at": "2026-10-23T05:02:35.277Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00095966" }, { "nct_id": "NCT02611037", "title": "Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Pleural Mesothelioma", "Mesothelioma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Lung Cancer Symptom Scale for Mesothelioma Questionnaire", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2016-03-04", "completion_date": "2024-01-26", "has_results": true, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-10-23T05:02:35.277Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02611037" }, { "nct_id": "NCT02082522", "title": "Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hilar Cholangiocarcinoma" ], "interventions": [ { "name": "Photodynamic therapy-Photofrin", "type": "DRUG" }, { "name": "Stenting procedure", "type": "PROCEDURE" }, { "name": "Chemotherapy regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Concordia Laboratories Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2014-11-12", "completion_date": "2017-01-12", "has_results": true, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-10-23T05:02:35.277Z", "location_count": 18, "location_summary": "Goodyear, Arizona • Scottsdale, Arizona • Los Angeles, California + 14 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02082522" }, { "nct_id": "NCT04974398", "title": "A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Nasopharyngeal Carcinoma" ], "interventions": [ { "name": "Penpulimab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akeso", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 296, "start_date": "2021-08-16", "completion_date": "2026-12-23", "has_results": false, "last_update_posted_date": "2025-04-13", "last_synced_at": "2026-10-23T05:02:35.277Z", "location_count": 5, "location_summary": "Duarte, California • Atlanta, Georgia • Ann Arbor, Michigan + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04974398" }, { "nct_id": "NCT06076837", "title": "The Seven Trial: Exploiting the Unfolded Protein Response", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer Metastatic", "Pancreatic Adenocarcinoma Metastatic" ], "interventions": [ { "name": "Botensilimab", "type": "DRUG" }, { "name": "Balstilimab", "type": "DRUG" }, { "name": "Chloroquine Phosphate", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HonorHealth Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2025-01-09", "completion_date": "2025-12-22", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-23T05:02:35.277Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06076837" }, { "nct_id": "NCT00246571", "title": "Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "SU011248", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 217, "start_date": "2006-01", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2012-07-12", "last_synced_at": "2026-10-23T05:02:35.277Z", "location_count": 77, "location_summary": "Corona, California • Fullerton, California • Glendora, California + 59 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Glendora", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00246571" }, { "nct_id": "NCT00003144", "title": "Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug/Agent Toxicity by Tissue/Organ", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "1997-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-03-28", "last_synced_at": "2026-10-23T05:02:35.277Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003144" }, { "nct_id": "NCT00151034", "title": "Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urologic Neoplasms" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2000-09", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2015-01-21", "last_synced_at": "2026-10-23T05:02:35.277Z", "location_count": 11, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00151034" }, { "nct_id": "NCT01385956", "title": "SOM 230 and Gemcitabine in Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "SOM 230 LAR", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2011-06", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2020-09-28", "last_synced_at": "2026-10-23T05:02:35.277Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01385956" }, { "nct_id": "NCT04697628", "title": "Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "tisotumab vedotin", "type": "DRUG" }, { "name": "topotecan", "type": "DRUG" }, { "name": "vinorelbine", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 502, "start_date": "2021-02-22", "completion_date": "2026-01-15", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-23T05:02:35.277Z", "location_count": 53, "location_summary": "Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 28 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04697628" } ] }